Mornings
Why the Wegovy pill only absorbs 1 to 2 percent
Because semaglutide is a peptide and the stomach digests peptides. The label puts the tablet's absolute bioavailability at approximately 1 to 2 percent, against 89 percent for the injection. Every morning rule exists to protect that small share: with food in the stomach, the manufacturer found no measurable drug at all in 14 of 26 volunteers.
DM, the one who read the label
Sources checked Sep 28, 2026
Published Sep 28, 2026
Updated Sep 28, 2026 · 2 min read
The short answer
Because semaglutide is a peptide and the stomach digests peptides. The label puts the tablet's absolute bioavailability at approximately 1 to 2 percent, against 89 percent for the injection. Every morning rule exists to protect that small share: with food in the stomach, the manufacturer found no measurable drug at all in 14 of 26 volunteers.
What the label says
The pharmacology section gives two numbers side by side.
From the labelAbsolute bioavailability of semaglutide is 89% following subcutaneous administration.
And for the tablet, approximately 1 to 2 percent. Nearly all of the semaglutide in a tablet never reaches the blood. The tablet is dosed knowing that: 25 mg a day, against 2.4 mg a week by injection, lands in the same range.
Why so little
Semaglutide is a peptide, a small protein, and the stomach is built to take proteins apart. The tablet carries a helper compound that shields the molecule for a while and helps a small share through the stomach wall. The label mentions that compound by name, SNAC, when it explains why breastfeeding is not recommended on the tablet.
That mechanism is fragile, and the label's morning rules are its instructions: an empty stomach so the tablet sits alone, a sip of water rather than a glass so it is not diluted, thirty minutes before anything else so the share has time to cross.
What the manufacturer measured
The clearest test was the one with food. Twenty-six volunteers took the tablet with a meal. In fourteen of them, no drug could be measured in the blood at all. In most of the others, barely any. One had a level comparable to the fasted state.
The other tests move the same number: a full glass of water instead of a sip, about 40 percent less; a 15 minute wait instead of 30, about half; a fast of a few hours instead of a night, 56 to 88 percent less.
What people actually do
On the forums the 1 to 2 percent is the fact people quote to each other when someone asks whether the rules really matter, usually in the form "these pills are expensive, don't waste them". It is also the fact that ends most debates about whether a small deviation counts: the share is small, and every rule guards it.
Oolite is built around that share: the timer, the reminder, the log of the mornings that went right. It does not measure absorption; nothing outside a lab does. It keeps the conditions.
Questions people ask
If only 1 to 2 percent gets in, how can 25 mg a day match 2.4 mg a week?
Because 25 mg a day is 175 mg a week, and one to two percent of that is in the range of the weekly injection. The label says the concentrations are comparable, with more variability on the tablet.
What makes the 1 to 2 percent possible at all?
A helper compound pressed into the tablet, which protects semaglutide in the stomach long enough for a share to cross. The label names it SNAC in its lactation section. It is why the tablet must be swallowed whole and taken with almost no water.
Does that mean most of the tablet is wasted?
Most of it is not absorbed, by design. The tablet is dosed for that. What is wasted is the morning that breaks the rules: food in the stomach, a full glass of water, a 15 minute wait.
Is Foundayo the same?
No. Orforglipron is not a peptide, and its label gives an absolute bioavailability of 77 percent, with no clinically relevant food effect. That is why Foundayo has no morning rules.
Sources
- Wegovy prescribing information, Novo Nordisk, §12.3, revised 06/2026 · Absolute bioavailability 89 percent for the injection, approximately 1 to 2 percent for the tablet; concentrations comparable with higher variability.
- FDA Clinical Pharmacology Review, NDA 213051 (oral semaglutide), 2019, study 4154 · Taken with food: 14 of 26 volunteers had no concentration above the lower limit of quantification.
- Foundayo prescribing information, Eli Lilly, §12.3, revised 07/2026 · Absolute bioavailability 77 percent; no clinically relevant food effect.
Sources checked Sep 28, 2026. This page is information, not medical advice: read the medical disclaimer, and talk to your prescriber or pharmacist about your own treatment.
Written by
DM, the one who read the label
I make Oolite. I read every label revision the day it comes out and rewrite these answers when they change.
How these pages are madeOolite
The GLP-1 tracker for the pill and the shot.
The 30 minute timer, your shot day, the level chart and the dose reminder, on iPhone, with Apple Watch to log. Free to download, then a 14-day free trial.
